A phase III clinical trial of the 6-month formulation of leuprorelin in patients with prostate cancer.

Trial Profile

A phase III clinical trial of the 6-month formulation of leuprorelin in patients with prostate cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Oct 2015 According to a Takeda media release, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for Leuprorelin (Leuplin) for the treatment of prostate cancer and premenopausal breast cancer.
    • 01 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top